Innoviva Inc (INVA) Stock Price, Quote & News

Company Profile

Innoviva, Inc. engages in the development and commercialization of pharmaceutical products in the United States and internationally. The company's products include RELVAR/BREO ELLIPTA, a once-daily combination medicine consisting of a LABA, vilanterol (VI), an inhaled corticosteroid (ICS), and fluticasone furoate; ANORO ELLIPTA, a once-daily medicine combining a long-acting muscarinic antagonist (LAMA) and umeclidinium bromide (UMEC) with a LABA, VI; GIAPREZA (angiotensin II), a vasoconstrictor...

Industry: Biotechnology

Sector: Healthcare

Phone: 650 238 9600

Website: www.inva.com

Address:

1350 Old Bayshore Highway, Suite 400, Burlingame, United States

All4Retiring Jan. 29 at 5:28 PM

$INVA The Innoviva competitor is asking $89 per tablet for Blujepa and 8 tablets are required for gonorrhea. Innoviva’s Zoliflodacin only requires 1 tablet. A clear advantage.

0 · Reply

AeroSmith Jan. 22 at 4:49 PM

$INVA Two 57 cent Qs in a row. PE of 14. Forward PE of 9. Turning up.

0 · Reply

ninergizer Jan. 20 at 10:35 PM

$INVA been in consolidation and should be ready for a break out. let's go! : )😃

0 · Reply

Tomorrowscoin Jan. 15 at 9:11 PM

$INVA I think I have a glitch in my account 😳

0 · Reply

ninergizer Jan. 14 at 11:47 PM

$ARWR $MIST $INVA First five on my list was approved $ATRA had CRL, waiting game until buy out or a meeting with FDA as this was already approved in EU. I have my next top 10 PDUFA coming soon.

1 · Reply

TheologyTinge Dec. 27 at 4:25 PM

$INVA Market participants want evidence that strategy converts to numbers; unit economics must show steady improvement — improving transparency could compress perceived risk. Execution quality is likely to be the main catalyst.

0 · Reply

Revaluation Dec. 26 at 3:55 PM

$INVA Considering entry here, anyone know why income is trending down so badly?

0 · Reply

AeroSmith Dec. 22 at 12:56 PM

$INVA Huge volume on Friday. Looks like a good entry spot here. PE of 14 ½ and a forward PE of 9 ½. Cheap.

0 · Reply

RunnerSignals Dec. 17 at 8:28 PM

$INVA $KVYO $IONQ Tech and biotech mashup alert! Growth royalties and quantum dreams collide eyes on these charts https://stocksrunner.com/news/2025-12-17-top-10-trending-stock-upgrades-today

0 · Reply

JarvisFlow Dec. 16 at 12:00 PM

HC Wainwright & Co. has adjusted their stance on Innoviva ( $INVA ), setting the rating to Buy with a target price of 45 → 46.

0 · Reply

U.S. FDA Approves NUZOLVENCE® (zoliflodacin), a First-in-Class, Single-dose, Oral Antibiotic for the Treatment of Uncomplicated Urogenital Gonorrhea in Adults and Adolescents

Dec 12, 2025, 1:33 PM EST - 7 weeks ago

US FDA approves Innoviva's oral antibiotic for common sexually transmitted infections

Dec 11, 2025, 6:35 PM EST - 7 weeks ago

Innoviva Specialty Therapeutics Announces Publication in The Lancet of Positive Zoliflodacin Phase 3 Data for the Treatment of Uncomplicated Urogenital Gonorrhea

Nov 25, 2025, 7:00 AM EST - 2 months ago

Innoviva to Participate in the 37th Annual Piper Sandler Healthcare Conference

Nov 5, 2025, 4:05 PM EST - 3 months ago

Innoviva Reports Third Quarter 2025 Financial Results; Highlights Recent Company Progress

Oct 21, 2025, 8:00 AM EDT - 3 months ago

Antheia Appoints Eric d'Esparbes as Chief Financial Officer

Oct 20, 2025, 8:00 AM EDT - 3 months ago

Innoviva Specialty Therapeutics Announces Oral Presentation Featuring New Analyses from the Zoliflodacin Pivotal Phase 3 Trial at IDWeek 2025

Oct 7, 2025, 8:00 AM EDT - 4 months ago

Innoviva Specialty Therapeutics to Deliver Six Presentations from its Infectious Diseases and Critical Care Portfolio at IDWeek 2025

Sep 2, 2025, 4:03 PM EDT - 5 months ago

Innoviva, Inc. (INVA) Presents At Citi's Biopharma Back To School Conference Transcript

Aug 26, 2025, 7:00 AM EDT - 5 months ago

Innoviva to Participate in Upcoming Investor Conferences

Aug 13, 2025, 8:00 AM EDT - 6 months ago

Innoviva Specialty Therapeutics' Antimicrobial Therapies ZEVTERA® and XACDURO® Nominated for the 2025 Prix Galien USA Best Pharmaceutical Product Award

Aug 6, 2025, 4:05 PM EDT - 6 months ago

Innoviva Reports Second Quarter 2025 Financial Results; Highlights Recent Company Progress

Jun 12, 2025, 7:00 AM EDT - 8 months ago

FDA Grants Priority Review for Zoliflodacin New Drug Application for the Treatment of Uncomplicated Gonorrhea and Assigns Target PDUFA Date of December 15, 2025

Jun 10, 2025, 6:00 AM EDT - 8 months ago

Innoviva Specialty Therapeutics Receives FDA New Drug Application Acceptance for Zoliflodacin, a First-in-Class Oral Antibiotic for Uncomplicated Gonorrhea in Adults

May 20, 2025, 6:00 AM EDT - 9 months ago

ZEVTERA® (ceftobiprole), an Advanced-Generation Cephalosporin Antibiotic Now Commercially Available in the U.S. to Treat Three Types of Bacterial Infections

May 20, 2025, 1:15 AM EDT - 9 months ago

Basilea announces commercial availability of antibiotic Zevtera® (ceftobiprole) in the United States

May 7, 2025, 4:05 PM EDT - 9 months ago

Innoviva Reports First Quarter 2025 Financial Results; Highlights Recent Company Progress

Mar 12, 2025, 5:08 PM EDT - 11 months ago

Armata Pharmaceuticals Announces $10 Million Secured Credit Agreement with Innoviva

ARMP

Mar 5, 2025, 7:00 AM EST - 11 months ago

Innoviva to Participate in the Barclays 27th Annual Global Healthcare Conference

Feb 26, 2025, 4:04 PM EST - 1 year ago

Innoviva Reports Fourth Quarter and Full Year 2024 Financial Results; Highlights Recent Company Progress

Feb 23, 2025, 1:11 AM EST - 1 year ago

Innoviva: Underappreciated Strength In Hospital Therapeutics

Feb 6, 2025, 7:00 AM EST - 1 year ago

Innoviva to Participate in the Oppenheimer 35th Annual Healthcare Life Sciences Conference

Dec 16, 2024, 7:00 AM EST - 1 year ago

Innoviva Specialty Therapeutics Signs Exclusive Distribution and Licensing Agreement to Acquire U.S. Marketing Rights for Zevtera® (ceftobiprole)

Dec 16, 2024, 1:15 AM EST - 1 year ago

Basilea announces agreement with Innoviva Specialty Therapeutics for the commercialization of antibiotic Zevtera® (ceftobiprole) in the United States

Nov 26, 2024, 7:00 AM EST - 1 year ago

Innoviva to Participate in the Citi 2024 Global Healthcare Conference

Nov 12, 2024, 4:05 PM EST - 1 year ago

Innoviva to Participate in the UBS Global Healthcare Conference

Nov 6, 2024, 4:05 PM EST - 1 year ago

Innoviva Reports Third Quarter 2024 Financial Results; Highlights Recent Company Progress

Oct 15, 2024, 7:00 AM EDT - 1 year ago

Innoviva Specialty Therapeutics to Present New Clinical Data From Its Development Pipeline and Broad Commercial Portfolio at IDWeek 2024

Jul 31, 2024, 4:05 PM EDT - 1 year ago

Innoviva Reports Second Quarter 2024 Financial Results; Highlights Recent Company Progress

Jun 18, 2024, 1:44 PM EDT - 1 year ago

Analyst Projects Strong Growth for GSK-Innoviva Partnered Respiratory Drugs

GSK

Jun 3, 2024, 7:00 AM EDT - 1 year ago

Innoviva to Participate in the Goldman Sachs 45th Annual Global Healthcare Conference

May 8, 2024, 4:05 PM EDT - 1 year ago

Innoviva Reports First Quarter 2024 Financial Results; Highlights Recent Company Progress

May 8, 2024, 7:00 AM EDT - 1 year ago

Innoviva to Participate in the BofA Securities Health Care Conference

Apr 24, 2024, 7:00 AM EDT - 1 year ago

Innoviva Specialty Therapeutics' Positive Phase 3 Oral Zoliflodacin Data for the Treatment of Uncomplicated Gonorrhea Announced at ESCMID Global 2024

Mar 4, 2024, 4:01 PM EST - 2 years ago

Armata Pharmaceuticals Announces $35 Million Secured Credit Agreement with Innoviva

ARMP

Feb 29, 2024, 4:05 PM EST - 2 years ago

Innoviva Reports Fourth Quarter and Full Year 2023 Financial Results; Highlights Recent Company Progress

Feb 28, 2024, 2:48 PM EST - 2 years ago

10 stocks you can bet on being inflation-proof

AM CW CXW HCC OTTR PCAR RDN

Nov 1, 2023, 4:15 PM EDT - 2 years ago

Innoviva Reports Third Quarter 2023 Financial Results and Highlights Recent Company Progress

Nov 1, 2023, 4:05 PM EDT - 2 years ago

Positive Results Announced in Largest Pivotal Phase 3 Trial of a First-in-Class Oral Antibiotic to Treat Uncomplicated Gonorrhea

Oct 11, 2023, 8:00 AM EDT - 2 years ago

Innoviva Specialty Therapeutics Presents New Data on its Critical Care Antibiotic Therapy Portfolio at Infectious Disease Week (IDWeek) 2023

Oct 9, 2023, 1:48 PM EDT - 2 years ago

Innoviva: A Lot Of Moving Parts

Sep 19, 2023, 8:30 AM EDT - 2 years ago

Innoviva to Participate in the Cantor Global Healthcare Conference

Sep 18, 2023, 8:00 AM EDT - 2 years ago

XACDURO®, The First and Only Antibiotic Developed to Target Acinetobacter, Now Available to Treat Hospital-Acquired Bacterial Pneumonia (HABP) and Ventilator-Associated Bacterial Pneumonia (VABP) in Adults

Aug 25, 2023, 4:52 PM EDT - 2 years ago

Innoviva Appoints Stephen Basso as Chief Financial Officer

Aug 2, 2023, 4:05 PM EDT - 2 years ago

Innoviva Reports Second Quarter 2023 Financial Results and Highlights Recent Company Progress

Jul 11, 2023, 8:00 AM EDT - 2 years ago

Armata Pharmaceuticals Announces New Financing and Leadership Transition to Accelerate Novel Bacteriophage Therapeutics

Jun 6, 2023, 4:05 PM EDT - 2 years ago

Innoviva to Participate in the Goldman Sachs Annual Global Healthcare Conference

May 23, 2023, 10:32 PM EDT - 2 years ago

FDA approves Innoviva's bacterial pneumonia treatment

May 23, 2023, 6:42 PM EDT - 2 years ago

Innoviva Specialty Therapeutics Announces FDA Approval for XACDURO® (sulbactam for injection; durlobactam for injection), Co-packaged for Intravenous Use

All4Retiring Jan. 29 at 5:28 PM

$INVA The Innoviva competitor is asking $89 per tablet for Blujepa and 8 tablets are required for gonorrhea. Innoviva’s Zoliflodacin only requires 1 tablet. A clear advantage.

0 · Reply

AeroSmith Jan. 22 at 4:49 PM

$INVA Two 57 cent Qs in a row. PE of 14. Forward PE of 9. Turning up.

0 · Reply

ninergizer Jan. 20 at 10:35 PM

$INVA been in consolidation and should be ready for a break out. let's go! : )😃

0 · Reply

Tomorrowscoin Jan. 15 at 9:11 PM

$INVA I think I have a glitch in my account 😳

0 · Reply

ninergizer Jan. 14 at 11:47 PM

$ARWR $MIST $INVA First five on my list was approved $ATRA had CRL, waiting game until buy out or a meeting with FDA as this was already approved in EU. I have my next top 10 PDUFA coming soon.

1 · Reply

TheologyTinge Dec. 27 at 4:25 PM

0 · Reply

Revaluation Dec. 26 at 3:55 PM

$INVA Considering entry here, anyone know why income is trending down so badly?

0 · Reply

AeroSmith Dec. 22 at 12:56 PM

$INVA Huge volume on Friday. Looks like a good entry spot here. PE of 14 ½ and a forward PE of 9 ½. Cheap.

0 · Reply

RunnerSignals Dec. 17 at 8:28 PM

$INVA $KVYO $IONQ Tech and biotech mashup alert! Growth royalties and quantum dreams collide eyes on these charts https://stocksrunner.com/news/2025-12-17-top-10-trending-stock-upgrades-today

0 · Reply

JarvisFlow Dec. 16 at 12:00 PM

HC Wainwright & Co. has adjusted their stance on Innoviva ( $INVA ), setting the rating to Buy with a target price of 45 → 46.

0 · Reply

All4Retiring Dec. 15 at 9:54 PM

$INVA We should see a nice pop once commercialization path is announced. INVA only has a hospital sales force. I would not be surprised if they sell this asset.

0 · Reply

ninergizer Dec. 15 at 9:31 PM

$INVA Nothing changed for me here. Long and strong : )

0 · Reply

5thElement Dec. 15 at 2:42 PM

$INVA I am surprised at the reaction, as gonorrhea is becoming much more difficult to treat due to multi drug resistance strains.

0 · Reply

BarelySocialGator Dec. 15 at 2:10 PM

$INVA I'm shocked. No love for the gonorrhea pill? 💊 😏

1 · Reply

jreddyN Dec. 15 at 7:12 AM

$INVA Undervalue stock

0 · Reply

jreddyN Dec. 14 at 2:56 PM

$INVA

0 · Reply

janed102 Dec. 13 at 7:24 PM

$INVA Institutions own over 95% of the total outstanding shares of Innoviva Inc. (INVA),

0 · Reply

janed102 Dec. 13 at 7:16 PM

$INVA discounted cash flow

0 · Reply

janed102 Dec. 13 at 1:58 PM

$INVA old news but interesting https://www.gsk.com/en-gb/media/press-releases/gsk-announces-sale-of-stake-in-innoviva-inc/

0 · Reply

All4Retiring Dec. 13 at 1:47 PM

$INVA I am trying to make sense of the 2nd half of 26 launch. Thoughts? It doesn’t tale that long to sign a partner.

2 · Reply

janed102 Dec. 13 at 11:58 AM

$INVA $125 million share repurchase program underway plus royalties from 7 respiratory co-produced products with GSK

0 · Reply

ninergizer Dec. 13 at 9:56 AM

$MIST $INVA both got approval on the same day. Congratulations to both companies!

1 · Reply

Market Cap	1.50B
Revenue (ttm)	358.71M
Net Income (ttm)	23.39M
EPS (ttm)	N/A
PE Ratio	7.40
Forward PE	9.23
Profit Margin	6.52%
Debt to Equity Ratio	0.25

Volume	922,700
Avg Vol	798,920
Day's Range	N/A - N/A
Shares Out	74.77M
Stochastic %K	100%
Beta	0.44
Analysts	Sell
Price Target	$32.50